Drugs / EBV-specific CTL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00078546 | Sep 2003 → Jan 2007 | Epstein-Barr virus infection, nasopharyngeal carcinoma | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific CTL | “Treatment of Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) with EBV-specific cytotoxic T cells (EBV-specific CTL) has been promising, producing clinical responses.” PMID 18971421 ↗ Oct 2008 |
| Known as | EBV-specific cytotoxic T cells | “Treatment of Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) with EBV-specific cytotoxic T cells (EBV-specific CTL) has been promising, producing clinical responses.” PMID 18971421 ↗ Oct 2008 |
| Modality | Cell therapy | “adoptively transferred EBV-specific CTL” PMID 18971421 ↗ Oct 2008 |
| Route | Intravenous | “EBV specific T cells will be given by intravenous injection over 1-10 minutes” NCT00078546 ↗ |